AtaiBeckley doses last patient in Elumina, phase 2b trial of VLS-01 in adults with treatment-resistant depression: New York Tuesday, July 7, 2026, 10:00 Hrs [IST] AtaiBeckley Inc.
A trial led by University of Pittsburgh researchers and published today in The Lancet Diabetes & Endocrinology adds nuance to ...
Discover how lion's mane mushroom supports brain health. Explore the clinical studies on memory, mycelium vs. extract, and ...
In this pooled analysis of randomized crossover trials, chronic mild sleep restriction was associated with modest increases ...
Morning Overview on MSN
Drinking more water measurably improved kidney health in a new study
A pilot randomized controlled trial in patients with stage 3 chronic kidney disease found that adding roughly one liter of ...
Morning Overview on MSN
Hearing aids didn’t sharpen memory, yet they lowered dementia risk anyway
Older adults who wore hearing aids for three years showed no broad improvement in memory or global cognition compared with a ...
While a single fecal microbiota transplantation session did not significantly improve multidrug-resistant organism ...
Introduction Bronchopulmonary dysplasia (BPD) remains a major complication among extremely low gestational age (ELGA) infants ...
AVE has made a breakthrough with a phase III insomnia trial for its soft gel cannabidiol to manage sleeplessness. AVE has ...
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced the ...
Phase 2b Elumina trial; topline data anticipated in Q4 2026 (ClinicalTrials.gov: NCT06524830) AtaiBeckley plans to advance VLS-01 into major depressive disorder (MDD) in Phase 3, with generalized ...
Candel Therapeutics (CADL) shifts to late-stage oncology with CAN-2409 Phase III wins and BLA catalyst. Read here for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results